{"nctId":"NCT01170221","briefTitle":"TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.","startDateStruct":{"date":"2010-08-15","type":"ACTUAL"},"conditions":["Skin and Subcutaneous Tissue Bacterial Infections"],"count":667,"armGroups":[{"label":"TR-701 FA","type":"EXPERIMENTAL","interventionNames":["Drug: TR-701 FA"]},{"label":"Linezolid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Linezolid"]}],"interventions":[{"name":"TR-701 FA","otherNames":["Tedizolid Phosphate","TR-700 active moiety"]},{"name":"Linezolid","otherNames":["Trade name = Zyvox","Generic name = linezolid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI)\n* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections\n\nExclusion Criteria:\n\n* Uncomplicated skin infections\n* Severe sepsis or septic shock\n* ABSSSI solely due to gram-negative pathogens","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Early Clinical Response Rate","description":"Responder: No increase in lesion surface area from baseline and oral temperature ≤37.6°C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at 48-72 Hours That is Sustained at the End of Therapy Visit.","description":"Responder: No increase in lesion surface area from baseline and oral temperature ≤37.6°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at 48-72 Hours That is Sustained at the End of Therapy Visit in the Clinically Evaluable-End of Therapy Analysis Sets","description":"Responder: No increase in lesion surface area from baseline and oral temperature ≤37.6°C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"232","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit","description":"Clinical success defined as resolution/near resolution of most disease-specific signs and symptoms, absence/near resolution of systemic signs of infection, if present at baseline, no new signs, symptoms, or complications attributable to the ABSSSIs so no further antibiotic therapy was required for the treatment of the primary lesion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"288","spread":null}]}]}]},{"type":"SECONDARY","title":"To Compare the Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit in the Clinically Evaluable-Post Treatment Evaluation Analysis Set","description":"Clinical success defined as resolution/near resolution of most disease-specific signs and symptoms, absence/near resolution of systemic signs of infection, no new signs, symptoms, or complications attributable to the ABSSSIs so no further antibiotic therapy was required for the treatment of the primary lesion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"267","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Response at the 48-72 Hour Visit","description":"Clinical improvement was defined as improvement in overall clinical status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"290","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Assessment of Clinical Response at the Day 7 Visit","description":"Clinical improvement was defined as improvement in overall clinical status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"302","spread":null},{"groupId":"OG001","value":"299","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-reported Pain, by Study Visit","description":"0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.05"},{"groupId":"OG001","value":"-1.5","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"2.44"},{"groupId":"OG001","value":"-3.1","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"2.71"},{"groupId":"OG001","value":"-4.6","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"2.65"},{"groupId":"OG001","value":"-5.5","spread":"2.58"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":331},"commonTop":["Nausea","Headache","Diarrhea","Vomiting","Abscess"]}}}